Cobenfy: A Discussion on the Newest Treatment for Schizophrenia

Panel moderated by Matcheri Keshavan, MD

Oliver Freudenreich, MD Psychiatrist
Peter J Weiden, MD Psychiatrist
Peter Durning, Lived Experience Consultant
Michael Angelini, PharmD Pharmacist

In September 2024, the Food and Drug Administration (FDA) approved the first novel medication for schizophrenia in nearly two decades. With the widespread interest around this new drug, Cobenfy, questions have been raised by providers and patients alike about how the drug works and what it means for the future of psychosis treatment. This panel will bring together experts with backgrounds in research, lived experience, and pharmacy to discuss Cobenfy and its potential impact on psychiatry.